title: Study designs for the nonclinical safety testing of new vaccine products.
abstract: During the development of a new vaccine, the purpose of nonclinical studies is to provide safety information to support the clinical development and licensure of the product. In this article the study designs currently accepted for the nonclinical safety testing of new vaccines are described for single dose, local tolerance, repeat dose toxicity and safety pharmacology studies; these studies together form the basis of a typical nonclinical safety evaluation dossier. The detailed design of the preclinical package must take account of the intended clinical use, patient population, route of administration, formulation, dose level and immunisation schedule. The test item that is used for these studies must be adequately representative of the intended clinical formulation. The animal model used for these studies must be selected on criteria of relevance. Single dose toxicity studies provide information on acute actions or the potential effect of accidental overdose, but this information is often available from the repeat dose toxicity study, obviating the need for the acute study. Local tolerance studies provide information on tissue reactions at the site of administration. Evaluation of the findings must distinguish between normal tissue responses to injected material and findings indicative of undesirable pathological changes. The repeated dose toxicity studies are the principal studies that support the safety profile of the vaccines. The design of these studies must take full account of the features of the vaccine in the choice of treatment regime, dose levels, pharmacodynamic monitoring and timing of investigations and sacrifice. Safety pharmacology studies are performed to evaluate the potential for undesirable secondary pharmacological actions of vaccines if there is data to suggest that such studies are needed; this evaluation is made on a case by case basis. In the absence of specific guidance the design of studies for therapeutic vaccines follows the same general principles as those for anti-infective vaccines.
authors.affiliation: CiToxLAB France, 27005 Evreux cedex, France. roy.forster@citoxlab.com
authors.forename: Roy
authors.initials: R
authors.lastname: Forster
mesh_terms: D000276:Adjuvants, Immunologic / Q000493:pharmacokinetics / Q000633:toxicity*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D007109:Immunity / Q000187:drug effects; D051379:Mice; D023421:Models, Animal; D011817:Rabbits; D051381:Rats; D012107:Research Design; D018570:Risk Assessment; D018675:Toxicity Tests / Q000379:methods*; D014612:Vaccines / Q000276:immunology / Q000493:pharmacokinetics / Q000633:toxicity*
chemical_list: D000276:Adjuvants, Immunologic; D014612:Vaccines